Is CRDL or CRSP more undervalued in 2026?

CirclFi compares Cardiol Therapeutics Inc. (CRDL) and CRISPR Therapeutics AG (CRSP) using 13 institutional-grade valuation models. CRDL has a Quality of Company score of 6.4/10 while CRSP scores 6.2/10.

Which is a better buy — CRDL or CRSP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRDL and CRSP valuations compare?

CRDL at $1.22 and CRSP at $56.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRDL vs CRSP Valuation Comparison 2026 — Intrinsic Value Analysis

CRDL

Biological Products, (No Diagnostic Substances)

Cardiol Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$1.22

Last close

Models

9/13

Active

CRSP

Biological Products, (No Diagnostic Substances)

CRISPR Therapeutics AG

Quality

6.2

out of 10

Value Trap

SAFE

Price

$56.18

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CRDL Fair Value	CRDL Upside	CRSP Fair Value	CRSP Upside
Bayesian DCF	Intrinsic	$0.42	-65.6%	$9.14	-83.7%
Earnings Power Value	Intrinsic	—	—	$27.66	-43.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.17	-86.0%	$8.56	-84.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRDL vs CRSP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRDL vs CRSP — Which Stock Is More Undervalued?

CRDL scores higher with a 6.4/10 quality rating vs CRSP's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cardiol Therapeutics Inc. (CRDL) and CRISPR Therapeutics AG (CRSP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRDL currently trades at $1.22 with a QOC of 6.4/10, while CRSP trades at $56.18 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).